WASHINGTON — The former top lawyer for Turing Pharmaceuticals says he and other executives warned Martin Shkreli against the drastic price hike that triggered a national backlash against the company and its 32-year-old CEO.
Turing’s former general counsel told Senate lawmakers Thursday that the fiftyfold price increase on Daraprim, a drug used to treat a life-threatening parasitic infection, “was not justified.”
Howard Dorfman, who left Turing last August, said that he and other staffers objected to the increase because it would have “a severely negative impact on Turing’s business and reputation.”
The Senate Aging Committee is scheduled to hear from current and former Turing executives, as well as an outside investor. Senators noted that Dorfman was subpoenaed to testify at the hearing
Shkreli, who is facing charges of securities fraud in New York, is not scheduled to appear. He resigned as CEO of Turing in December after his indictment.
Thursday’s hearing marks the second time in two months that lawmakers have summoned Turing executives to account for their pricing tactics. Last month House lawmakers subpoenaed Shkreli to appear at a similar hearing, though he declined to answer questions, citing his Fifth Amendment right.
Turing has been almost universally condemned for purchasing the only approved drug for a rare infection that mainly affects AIDS and cancer patients and then increasing the price to $750 per pill. The drug sells overseas for as little as $2.
After coming under fire last fall, Turing responded that it was investing the profits from the increase into a “next generation” treatment that would be superior to Daraprim. But Dorfman says that there was no research plan for such an effort.
“In this instance, the price increase, as contemplated and subsequently announced, was not justified by any such actual expenditure,” he testified.
Public concerns about sky-high drug prices have been growing for years but boiled over after media coverage of the price hike and Shkreli’s outspoken pushback, often taunting politicians and public figures over social media.
Many pharmaceutical companies increase prices annually as a matter of doing business. But the staggering size of increases by Turing and a handful of other drugmakers turned drug pricing into a national issue, reverberating from late night TV to the presidential campaign trail.
The blatant price gouging seemed to confirm the public’s worst fears about pharmaceutical companies: that they are more Wall Street-driven investment vehicles than actual makers of medicines.
Shkreli’s prior work as a hedge fund manager ultimately landed him in court.
Prosecutors in December accused him of losing investors’ money through bad trades and then looting Retrophin (RTRX), another pharmaceutical company where he was CEO, for $11 million to pay back his disgruntled hedge fund investors. Shkreli has pleaded not guilty and is out on $5 million bail.